Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination-Reference-Cited by-同舟云学术

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

Published:2022-03-01 Issue:3 Volume:79 Page:307
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

König Marton¹,Torgauten Hilde Marie²,Tran The Trung³,Holmøy Trygve⁴,Vaage John Torgils³,Lund-Johansen Fridtjof³,Nygaard Gro Owren¹

Affiliation:

1. Department of Neurology, Oslo University Hospital, Oslo, Norway

2. Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway

3. Department of Immunology, Oslo University Hospital, Oslo, Norway

4. Department of Neurology, Akershus University Hospital, Oslo, Norway

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2787974/jamaneurology_knig_2022_ld_210015_1646836697.39518.pdf

Reference6 articles.

1. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.;Achiron;Ther Adv Neurol Disord,2021

2. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.;König;J Neurol Neurosurg Psychiatry,2021

3. Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab.;Brill;JAMA Neurol,2021

4. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.;Holter;Proc Natl Acad Sci U S A,2020

5. Evidence for antibody as a protective correlate for COVID-19 vaccines.;Earle;Vaccine,2021

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study;BMC Neurology;2024-08-20

2. Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study;Frontiers in Immunology;2024-08-19

3. Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination;Frontiers in Immunology;2024-07-15

4. Impact of multiple doses of vaccination on epidemiological spread in multiple networks;Applied Mathematics and Computation;2024-07

5. Long-Term Observation of SARS-CoV-2 Vaccination Response upon High Efficacy Treatment in Multiple Sclerosis—A Real-World Scenario;Vaccines;2024-03-12